Physician profile
John A Cox
NPI 1174796544
$4,805.64
in general payments reported to CMS, 2019-2025
64 companies · $349 in 2025
The $349 reported for 2025 was more than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $609 · 2020: $267 · 2021: $786 · 2022: $850 · 2023: $1,722 · 2024: $224 · 2025: $349.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,295.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,295.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $373.93 | 2019-2023 | Keytruda, Lynparza, Welireg |
| Novartis Pharmaceuticals Corporation | $354.35 | 2021-2025 | Kisqali, Piqray |
| Amgen INC. | $330.67 | 2019-2023 | Lumakras |
| Astrazeneca Pharmaceuticals LP | $284.22 | 2019-2025 | Tagrisso, Lynparza |
| Incyte Corporation | $239.30 | 2019-2023 | Monjuvi, Jakafi, Pemazyre |
| Genzyme Corporation | $203.77 | 2019-2023 | |
| Pfizer INC. | $191.75 | 2022-2025 | |
| Daiichi Sankyo INC. | $172.95 | 2019-2024 | Enhertu, Injectafer |
| E.R. Squibb & Sons, L.L.C. | $161.19 | 2022-2024 | Opdivo, Opdualag |
| Seagen INC. | $160.62 | 2019-2023 | Padcev, Tukysa |
| Janssen Biotech, INC. | $146.96 | 2019-2025 | Tecvayli, Erleada |
| Takeda Pharmaceuticals U.S.A., INC. | $121.38 | 2019-2025 | Iclusig, Alunbrig, Ninlaro |
| Eisai INC. | $110.11 | 2019-2025 | |
| Lilly USA, LLC | $105.56 | 2019-2023 | Jaypirca, Retevmo, Verzenio |
| Ipsen Biopharmaceuticals, INC | $101.12 | 2020-2023 | Somatuline Depot, Onivyde |
Show all 64 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Cox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.